Pain management in osteoarthritis: A focus on onset of efficacy - A comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials

Wendy P. Battisti, Nathaniel P. Katz, Arthur L. Weaver, Alan K. Matsumoto, Alan J. Kivitz, Adam B. Polis, Gregory P. Geba

Research output: Contribution to journalArticle

Abstract

We compared onset of efficacy (during days 1 to 6) of 2 coxibs (rofecoxib, celecoxib) with acetaminophen and nabumetone by using a prespecified approach to data from 4 similarly designed 6-week randomized osteoarthritis trials. In 2 trials, rofecoxib (12.5 mg and 25 mg once daily) was compared with celecoxib (200 mg once daily) and acetaminophen (4000 mg daily). In the other 2 trials, rofecoxib (12.5 mg) was compared with nabumetone (1000 mg once daily) and placebo. Efficacy end points included Patient Global Response to Therapy and Western Ontario and McMaster Osteoarthritis Index scores. Rofecoxib (12.5- and 25-mg doses) consistently demonstrated a faster onset of osteoarthritis (OA) efficacy than the comparator drugs during the first 6 days of therapy of OA patients experiencing "flare." Acetaminophen resulted in the slowest onset of efficacy. There was a strong correlation (0.7) between efficacy response during days 1 to 6 and that averaged over 6 weeks. Rates of discontinuation as a result of lack of efficacy were significantly lower (P <. 02) for each of the coxib-treated groups compared with acetaminophen and for rofecoxib 12.5 mg (P =. 01) compared with nabumetone. Rofecoxib treatment, with its faster onset of OA efficacy and lower rates of related discontinuations, might provide efficacy advantages in the treatment of OA pain. The efficacy of rofecoxib, celecoxib, nabumetone, and acetaminophen is established for the majority of OA patients within the first 6 days of therapy, and this predicts efficacy during the longer term. Rofecoxib provides significantly faster time to onset of efficacy and better improvement on multiple measures versus the comparators.

Original languageEnglish (US)
Pages (from-to)511-520
Number of pages10
JournalJournal of Pain
Volume5
Issue number9
DOIs
StatePublished - Nov 1 2004

Keywords

  • NSAIDs.
  • Osteoarthritis
  • efficacy onset
  • pain management

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Fingerprint Dive into the research topics of 'Pain management in osteoarthritis: A focus on onset of efficacy - A comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials'. Together they form a unique fingerprint.

  • Cite this